A5011608816- Breast Cancer Treatment Studies
- Economic and Financial Impacts of Cancer
- Global Cancer Incidence and Screening
- Cancer Treatment and Pharmacology
- Health Systems, Economic Evaluations, Quality of Life
- BRCA gene mutations in cancer
- Breast Lesions and Carcinomas
- Cancer Genomics and Diagnostics
- Estrogen and related hormone effects
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Advances in Oncology and Radiotherapy
- Cancer survivorship and care
- Childhood Cancer Survivors' Quality of Life
- Palliative Care and End-of-Life Issues
- Cancer Risks and Factors
- Colorectal Cancer Treatments and Studies
- Colorectal Cancer Screening and Detection
- Lung Cancer Treatments and Mutations
- Clinical practice guidelines implementation
- Semantic Web and Ontologies
- Electronic Health Records Systems
- Healthcare cost, quality, practices
- Astro and Planetary Science
- Nutrition, Genetics, and Disease
National Comprehensive Cancer Network
2015-2024
Stanford University
2010-2023
Palo Alto University
1997-2023
Stanford Medicine
2000-2022
The University of Texas MD Anderson Cancer Center
2010-2022
Pancreatic Cancer Action Network
2017-2022
North Central Cancer Treatment Group
2021
Fox Chase Cancer Center
2014-2021
UNC Lineberger Comprehensive Cancer Center
2014-2021
Memorial Sloan Kettering Cancer Center
2006-2019
Evidence is lacking that a dietary pattern high in vegetables, fruit, and fiber low total fat can influence breast cancer recurrence or survival.
Background To improve cancer therapy, it is critical to target metastasizing cells. Circulating tumor cells (CTCs) are rare found in the blood of patients with solid tumors and may play a key role dissemination. Uncovering CTC phenotypes offers potential avenue inform treatment. However, transcriptional profiling limited by leukocyte contamination; an approach surmount this problem single cell analysis. Here we demonstrate feasibility performing high dimensional profiling, providing early...
Breast cancer outcomes in low- and middle-income countries (LMCs) correlate with the degree to which 1) cancers are detected at early stages, 2) newly can be diagnosed correctly, 3) appropriately selected multimodality treatment provided properly a timely fashion. The Health Global Initiative (BHGI) invited international experts review revise previously developed BHGI resource-stratified guideline tables for detection, diagnosis, treatment, healthcare systems. Focus groups addressed specific...
<h3>Background</h3> Metastatic breast cancer carries with it considerable psychosocial morbidity. Studies have shown that some patients metastatic experience clinically significant anxiety and depression traumatic stress symptoms. Supportive-expressive group psychotherapy was developed to help face adjust their existential concerns, express manage disease-related emotions, increase social support, enhance relationships family physicians, improve symptom control. <h3>Methods</h3> Of 125 women...
Background.The impact of the surgical margin status on long term local control rates for breast cancer in women treated with lumpectomy and radiation therapy is unclear.Methods.The records 289 303 invasive cancers who were from 1972 to 1992 reviewed.The was classified as positive (transecting inked margin), close (less than or equal 2 mm negative, indeterminate, based initial biopsy findings reexcision specimens, appropriate.Various clinical pathologic factors analyzed potential prognostic...
Abstract: Breast cancer is the most common cause of cancer-related death among women worldwide, with case fatality rates highest in low-resource countries. Despite significant scientific advances its management, world faces resource constraints that limit capacity to improve early detection, diagnosis, and treatment disease. The Health Global Initiative (BHGI) strives develop evidence-based, economically feasible, culturally appropriate guidelines can be used nations limited health care...
Purpose There is a lack of treatments providing survival benefit for patients with metastatic triple-negative breast cancer (mTNBC), no standard care. A randomized phase II trial showed significant gemcitabine, carboplatin, and iniparib (GCI) over gemcitabine carboplatin (GC) in clinical rate, response progression-free (PFS), overall (OS). Here, we formally compare the efficacy these regimens III trial. Patients Methods stage IV/locally recurrent TNBC who had received more than two previous...
The Breast Health Global Initiative (BHGI) brought together international breast cancer experts to discuss in low resource countries (LRCs) and identify common concerns reviewed this consensus statement. There continues be a lack of public health care professionals' awareness the importance early detection cancer. Mastectomy most treatment for cancer; surgeons anesthesia services was identified as contributing factor delayed surgical therapy LRCs. Where available, radiation is still more...
Trastuzumab, a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2; also known as HER-2/neu), is indicated for the treatment of women with either early stage or metastatic HER2+ breast cancer. It kills tumor cells by several mechanisms, including antibody-dependent cellular cytotoxicity (ADCC). Strategies that enhance activity ADCC effectors, NK cells, may improve efficacy trastuzumab. Here, we have shown upon encountering trastuzumab-coated, HER2-overexpressing...
This study was designed to assess efficacy, safety, and predictors of response iniparib in combination with gemcitabine carboplatin early-stage triple-negative BRCA1/2 mutation-associated breast cancer.This single-arm phase II enrolled patients stage I IIIA (T ≥ 1 cm) estrogen receptor-negative (≤ 5%), progesterone human epidermal growth factor receptor 2-negative or cancer. Neoadjuvant (1,000 mg/m(2) intravenously [IV] on days 8), (area under curve 2 IV (5.6 mg/kg 1, 4, 8, 11) were...
This study was designed to replicate our earlier finding that intensive group therapy extended survival time of women with metastatic breast cancer. Subsequent findings concerning the question whether such psychosocial support affects have been mixed.One hundred twenty-five confirmed (n = 122) or locally recurrent 3) cancer were randomly assigned either supportive-expressive condition 64), where they received educational materials plus weekly therapy, control 61), only for a minimum 1 year....
Current practice is to perform a completion axillary lymph node dissection (ALND) for breast cancer patients with tumor-involved sentinel nodes (SLNs), although fewer than half will have non-sentinel (NSLN) metastasis. Our goal was develop new models quantify the risk of NSLN metastasis in SLN-positive and compare predictive capabilities another widely used model.We constructed three predict status: recursive partitioning receiver operating characteristic curves (RP-ROC), boosted...
Immune dysfunction develops in patients with many cancer types and may contribute to tumor progression failure of immunotherapy. Mechanisms underlying cancer-associated immune are not fully understood. Efficient IFN signaling is critical lymphocyte function; animals rendered deficient develop at higher rates. We hypothesized that altered be a key mechanism common cancer. To address this, we assessed the functional responses peripheral blood lymphocytes from 3 major cancers: breast cancer,...
The NCCN HER2 Testing in Breast Cancer Task Force was convened to critically evaluate the ability of level expression or gene amplification breast cancer tumors serve as a prognostic and predictive factor metastatic adjuvant settings, assess reliability methods measuring laboratory, make recommendations regarding interpretation test results. is multidisciplinary panel 24 experts representing disciplines medical oncology, pathology, radiation surgical epidemiology, patient advocacy. Invited...
These NCCN Guidelines Insights highlight the important updates specific to management of HER2-positive metastatic breast cancer in 2013 version Clinical Practice Oncology for Breast Cancer. include new first-line and subsequent therapy options patients with cancer.